Most Popular
View all6
Share this post
Provectus Announces Investor Conference Call: November 14th at 2 pm ET
provectus.substack.com
3
Share this post
Rose Bengal Photodynamic Antimicrobial Therapy for Infectious Keratitis
provectus.substack.com
6
Share this post
Building Trust: Bascom Palmer Eye Institute, Provectus Biopharmaceuticals, and RBS PDAT
provectus.substack.com
6
Share this post
Cancer immunotherapy PV-10’s evolution into a cancer immunotherapy
provectus.substack.com
2
Share this post
Provectus Announces Investor Webinar of 2024 Annual Meeting for June 20th at 4 pm ET
provectus.substack.com
Provectus’s Substack
A clinical-stage biotechnology company developing immunotherapy medicines for different diseases based on a class of synthetic small molecule halogenated xanthenes, with lead molecule rose bengal sodium.
Share this publication
Provectus’s Substack
provectus.substack.com
© 2024 Provectus Biopharmaceuticals, Inc.
Substack is the home for great culture